Why TransMedics Fell 15.7% This Week

Source The Motley Fool

Shares of organ transplant innovator TransMedics Group (NASDAQ: TMDX) fell 15.7% through Thursday trading, according to data from S&P Global Market Intelligence.

TransMedics was the target of an activist short-seller late last week, and on Monday of this week, the company responded to the accusations at an industry health conference.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. See the 10 stocks »

While the stock initially bounced back a bit after the conference, it continued to fall through the week, as investors still appear to be skittish over the controversy.

Scorpion attacks

Last Friday, Scorpion Capital published a 342-page short report -- yes, 342 pages! -- detailing an alleged six-month investigation into TransMedics and its business practices.

TransMedics has developed a new type of organ transplant technology called the Organ Care System (OCS), which provides oxygen and nutrients to organs during transport. This new technology aims to supplant the current standard of cold storage, which is basically freezing the organ.

Scorpion's report includes a number of allegations. Some of these are that the OCS doesn't work nearly as well as the company lets on, that TransMedics uses thuggish tactics to get hospitals to take on its organs and to push sales, and that the company has antagonized customers by withholding organs if payments haven't come through. Scorpion also pointed to emerging competitive concerns, among other issues.

On Monday, TransMedics gave a full-throated defense of its business in a press release, and also in its presentation at the J. P. Morgan Healthcare Conference. The press release said Scorpion's report had "no merits" and that it "fails to accurately represent TransMedics' business, technology, diverse culture and steadfast focus on delivering exceptional products and services to meet the needs of the global transplant community." The company also said it was engaging a law firm to discuss legal options.

In the first part of his presentation at the conference, CEO Waleed Hassanein suggested that since TransMedics is in the process of disrupting established players in organ transplant, those competitors may be "driving a lot of the dynamics you guys are seeing" regarding the short report.

Who should investors believe?

TransMedics can't seem to catch a break recently, as the company disappointed investors with a growth slowdown in its third-quarter earnings release and fourth-quarter guidance. Its CFO also stepped down back in December. The stock is now down 66% from its all-time highs, reached just this past summer.

If the Scorpion report turns out to have some truth, there is obviously further downside. However, if TransMedics is correct and its technology and business are eventually vindicated, the upside potential is still substantial, according to the company's long-term guidance.

Interested investors may want to take a page out of Peter Lynch's book and "invest in what you know." For instance, if you happen to know a surgeon, other physician, nurse, or administrator who works with organ transplants, questioning them as to whether they've worked with TransMedics' OCS and how they did with the technology could yield insights into this controversial stock. Otherwise, it may be hard to build conviction until more information comes to light.

Should you invest $1,000 in TransMedics Group right now?

Before you buy stock in TransMedics Group, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and TransMedics Group wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $818,587!*

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.

See the 10 stocks »

*Stock Advisor returns as of January 13, 2025

JPMorgan Chase is an advertising partner of Motley Fool Money. Billy Duberstein and/or his clients have no position in any of the stocks mentioned. The Motley Fool has positions in and recommends JPMorgan Chase and TransMedics Group. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Nvidia stock sinks 4% as Trump’s tariff plans rattle AI tradeNvidia shares fell over 4% early Monday after US President Donald Trump delivered a stern message about trade tariffs. Trump said on Sunday that no country would be given any special treatment regarding tariffs. He also signed new trade policies into effect on April 2, which he calls “Liberation Day.” This frightened investors, who had […]
Author  NewsBTC
Apr 01, Tue
Nvidia shares fell over 4% early Monday after US President Donald Trump delivered a stern message about trade tariffs. Trump said on Sunday that no country would be given any special treatment regarding tariffs. He also signed new trade policies into effect on April 2, which he calls “Liberation Day.” This frightened investors, who had […]
placeholder
Bitcoin Price Bounces Back—Can It Finally Break Resistance?Bitcoin price started a recovery wave above the $83,500 zone. BTC is now consolidating and might struggle to settle above the $85,500 zone. Bitcoin started a decent recovery wave above the $83,500
Author  NewsBTC
23 hours ago
Bitcoin price started a recovery wave above the $83,500 zone. BTC is now consolidating and might struggle to settle above the $85,500 zone. Bitcoin started a decent recovery wave above the $83,500
placeholder
Bitcoin Price Struggling but Short-Term Holders Might Be Setting the Stage for $150KBitcoin has recently displayed signs of upward momentum, trading at $85,215, marking a 2.2% increase in just the past day. Despite this short-term gain, the asset remains down by over 21.2% from its
Author  NewsBTC
18 hours ago
Bitcoin has recently displayed signs of upward momentum, trading at $85,215, marking a 2.2% increase in just the past day. Despite this short-term gain, the asset remains down by over 21.2% from its
placeholder
U.S. March Nonfarm Payroll Preview: Even If Data Aligns with Expectations, Financial Markets May Not Escape the Fate of VolatilityOn 4 April 2025, the United States will release its March Nonfarm Payrolls (NFP) data. The market consensus currently anticipates job growth of 128,000, a decline from February’s 151,000 (Figure 1). W
Author  TradingKey
17 hours ago
On 4 April 2025, the United States will release its March Nonfarm Payrolls (NFP) data. The market consensus currently anticipates job growth of 128,000, a decline from February’s 151,000 (Figure 1). W
placeholder
Gold price stabilizes ahead of Trump's tariffs announcement on “Liberation Day”Gold price (XAU/USD) stabilizes just above $3,130 at the time of writing on Wednesday following a mean reversal move the prior day after a fresh all-time high got eked out at $3,149 before closing in negative territory.
Author  FXStreet
16 hours ago
Gold price (XAU/USD) stabilizes just above $3,130 at the time of writing on Wednesday following a mean reversal move the prior day after a fresh all-time high got eked out at $3,149 before closing in negative territory.
goTop
quote